- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Generalised myasthenia gravis (gMG)
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 572.9KB)
- Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 163.3KB)
Efgartigimod alfa – November 2025
Efgartigimod alfa: Solution for subcutaneous injection 1000 mg in 5.6 mL; Vyvgart® - November 2025
Last updated
5 November 2025